Wegovy Cost in New York 2026: Cash Pay, Insurance, and Savings Options

What Does Wegovy Actually Cost in New York Right Now?

Wegovy's manufacturer list price in New York is $1,349 per month in 2026, identical to the national Novo Nordisk wholesale acquisition cost. That figure rarely reflects what a real patient pays. Cash-pay patients at retail pharmacies across the state, including Duane Reade, CVS, Rite Aid, and Costco, will typically see prices close to that list price without any assistance program.

The gap between list price and actual out-of-pocket cost depends almost entirely on which coverage pathway a patient uses. The three main pathways in New York are commercial insurance (with or without the Novo Nordisk savings card), New York Medicaid, and compounded semaglutide through a licensed 503A pharmacy.

Why List Price Is Not the Real Price for Most Patients

Pharmacy benefit managers (PBMs) negotiate rebates that reduce what insurers pay, but those discounts do not automatically pass through to patients at the counter. A patient with a high-deductible health plan may owe the full adjudicated cost until their deductible resets. The Novo Nordisk savings card specifically targets this problem for commercially insured patients.

Retail Pharmacy Price Benchmarks in 2026

Across New York retail pharmacies, the 28-day supply of Wegovy (four 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, or 2.4 mg pens, depending on dose step) lists at $1,349. GoodRx coupons may lower that to roughly $1,100 to $1,200 at select pharmacies, though coupon pricing shifts weekly. These coupons are incompatible with insurance benefits and cannot be combined with the Novo Nordisk savings card.

How Commercial Insurance Covers Wegovy in New York

Coverage for Wegovy under commercial insurance in New York varies by employer plan, insurer, and plan tier. The Affordable Care Act does not require commercial insurers to cover obesity medications; coverage is an employer or insurer decision.

Which Plans Are Most Likely to Cover It

The largest commercial insurers operating in New York, including Empire BlueCross BlueShield, United Healthcare, Aetna, Cigna, and Oscar Health, have each added GLP-1 obesity treatments to at least some formularies since 2023. Whether your specific plan covers Wegovy depends on the plan documents. Key questions to ask your HR department or insurer are: (1) Is semaglutide 2.4 mg (Wegovy) on the formulary? (2) Is prior authorization required? (3) What BMI or comorbidity criteria must be documented?

Prior Authorization Criteria

Most commercial plans that cover Wegovy in New York require prior authorization. Standard criteria align with the FDA label: a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher plus at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The FDA approved semaglutide 2.4 mg on June 4, 2021. [1]

Insurers often also require documented participation in a behavioral weight management program and evidence that the prescribing clinician has counseled the patient on diet and exercise.

Step Therapy Requirements

Several New York commercial plans require step therapy, meaning a patient must try and fail (or have a documented contraindication to) an older anti-obesity medication before Wegovy is approved. Phentermine-topiramate (Qsymia) and bupropion-naltrexone (Contrave) are common step agents. Step therapy adds weeks to the prior authorization process.

New York Medicaid and Wegovy: Coverage With Prior Authorization

New York Medicaid covers Wegovy for chronic weight management with prior authorization. This is meaningful: not all state Medicaid programs cover GLP-1 obesity agents, and New York's inclusion puts it ahead of many states.

Who Qualifies Under New York Medicaid

New York Medicaid follows criteria consistent with the FDA-approved label. A prescribing clinician must document BMI of 30 or greater, or BMI of 27 or greater with an obesity-related comorbidity. Prior authorization requests go through eMedNY, the state's Medicaid management information system.

What the Coverage Includes

Once approved, New York Medicaid covers the full dose escalation from 0.25 mg weekly up to the maintenance dose of 2.4 mg weekly across the recommended 16-to-20-week titration schedule. Coverage is subject to annual reauthorization in most cases, requiring updated documentation of clinical benefit, typically defined as at least 5% body weight reduction from baseline.

Empire BlueCross Medicaid Managed Care

Many New York Medicaid enrollees receive benefits through a managed care organization (MCO) rather than fee-for-service Medicaid. Empire BlueCross, Fidelis Care, MetroPlusHealth, and others administer Medicaid managed care in New York City and statewide. Each MCO may apply slightly different PA criteria. Contacting the MCO's pharmacy benefits line directly is the fastest way to confirm current criteria.

The Novo Nordisk Savings Card: How It Works in New York

The Novo Nordisk savings card (marketed as the WeGo(Rx) savings program, previously the "Wegovy SavingsRx" card) allows eligible commercially insured patients in New York to pay as little as $0 per month for Wegovy.

Eligibility Requirements

To use the savings card, a patient must:

• Have commercial (private) insurance that covers Wegovy
• Not be enrolled in any federal or state government insurance program, including Medicaid, Medicare Part D, or any other federal benefit program
• Be a U.S. Resident

New York residents enrolled in both a commercial plan and a government-funded secondary plan are not eligible. The savings card cannot be used with Medicaid, Medicare, or Tricare.

How the Benefit Is Applied

The card acts as a secondary payer. After the commercial insurer adjudicates the claim, the savings card covers the remaining patient cost-share up to the program's monthly cap. For most commercially insured New York patients in 2026, this means $0 out-of-pocket per monthly fill as long as their plan covers the drug. Patients access the card through NovoCare at 1-833-NOVO-411 or via the Novo Nordisk website.

If Your Insurance Does Not Cover Wegovy

Patients whose commercial insurance does not cover Wegovy are not eligible for the $0 offer. A limited uninsured/underinsured savings option may reduce monthly costs by a fixed dollar amount, though the cash-pay net price remains above $1,000 per month for most patients in this situation.

Compounded Semaglutide 2.4 mg in New York: Legality and Access in 2026

Compounded semaglutide 2.4 mg is available through licensed 503A pharmacies in New York at approximately $199 per month in 2026. Whether compounding remains legal at any given time depends on the FDA's current shortage determination for Wegovy.

The 503A Framework and New York State Board of Pharmacy

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may prepare copies of FDA-approved drugs when a shortage has been declared. [2] When FDA removes a drug from the shortage list, 503A pharmacies are given a wind-down period before they must stop compounding that drug.

New York State's pharmacy compounding rules are enforced by the New York State Board of Pharmacy and align with federal 503A standards. Compounding pharmacies in New York must compound from pharmaceutical-grade active pharmaceutical ingredients (API), maintain proper sterile compounding standards for injectable products, and dispense only pursuant to a valid patient-specific prescription from a licensed prescriber.

Shortage Status as of 2026

The FDA added semaglutide injection to its drug shortage database in 2022. In early 2025, the FDA announced that the shortage for Wegovy had been resolved, triggering a phased enforcement timeline. Patients and clinicians should check the FDA drug shortage database directly, because the shortage status can change and determines whether a New York 503A pharmacy may legally compound semaglutide on any given date. [3]

Quality and Safety Considerations

Compounded semaglutide is not FDA-approved. It has not undergone the same manufacturing inspections as the branded product. The FDA issued multiple safety communications in 2024 and 2025 noting reports of dosing errors associated with compounded semaglutide products, some involving concentrations significantly different from the commercial pen. [4] Patients choosing compounded semaglutide should confirm that their pharmacy holds a current New York State license, compounds under USP 797 sterile standards, and dispenses with clearly labeled concentration information.

HealthRX Cost-Decision Framework for New York Patients (2026)

Use this sequence to find the lowest legal cost for Wegovy in New York:

1. Commercial insurance with savings card. Check whether your plan covers Wegovy (formulary lookup or HR call). If yes and the savings card applies, cost may be $0 per month.
2. New York Medicaid. If you are enrolled, request prior authorization through your MCO or fee-for-service Medicaid. Coverage is available with documentation.
3. Compounded semaglutide via licensed NY 503A pharmacy. Confirm current FDA shortage status before proceeding. Cost is roughly $199 per month but quality assurance and legal status require verification.
4. NovoCare patient assistance. For patients who cannot afford Wegovy and do not qualify for the savings card, Novo Nordisk's patient assistance program (PAP) may provide the drug at no cost. Eligibility is income-based; apply through NovoCare.
5. Cash pay at retail. The last option. Approximately $1,349 per month with no savings pathway applied.

Clinical Evidence: Why the Cost May Be Justified

Wegovy's price in New York is high, but the clinical data from STEP-1 are specific. In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg once weekly achieved a mean body weight reduction of 14.9% at 68 weeks compared with 2.4% in the placebo group (P<0.001). [5] That translates to approximately 15.3 kg (33.7 lb) of mean weight loss in the active treatment group.

The SELECT Cardiovascular Trial

For patients with established cardiovascular disease, the SELECT trial (N=17,604) showed that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 20% compared with placebo over a mean follow-up of 39.8 months (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). [6] The FDA subsequently updated the Wegovy label in March 2024 to include cardiovascular risk reduction as an approved indication for adults with established cardiovascular disease and either obesity or overweight.

The Endocrine Society's 2023 Clinical Practice Guideline on obesity pharmacotherapy states: "We recommend use of one of the more effective anti-obesity medications (phentermine/topiramate ER, naltrexone/bupropion ER, liraglutide, or semaglutide 2.4 mg weekly) in combination with lifestyle intervention, and not lifestyle intervention alone, in adults with obesity or overweight." [7]

Dose Titration and Duration

The approved titration schedule starts at 0.25 mg once weekly for four weeks, then 0.5 mg for four weeks, 1.0 mg for four weeks, 1.7 mg for four weeks, and finally 2.4 mg weekly as the maintenance dose. Patients who cannot tolerate 2.4 mg may remain at 1.7 mg. The clinical trials ran for 68 weeks; real-world use is typically indefinite, as weight often returns after discontinuation. [8]

Getting Wegovy via Telehealth in New York

Telehealth prescribing of Wegovy is legal in New York. A licensed New York physician or nurse practitioner may evaluate a patient via a synchronous (video or audio) telehealth visit and, if clinically appropriate, transmit a prescription for Wegovy to a New York pharmacy.

New York Telehealth Prescribing Rules

New York requires that telehealth prescribing be conducted by a clinician who holds an active New York State license. A prior clinician-patient relationship is not required for controlled substances under the telehealth rules that govern non-controlled medications like Wegovy. The clinician must document a clinical evaluation, diagnosis, and treatment plan in the medical record, identical to the standards for in-person care.

What to Expect From a Telehealth Wegovy Visit

A typical telehealth obesity visit in New York includes a review of weight history, BMI calculation, comorbidity screening (blood pressure, lipids, glucose or HbA1c, thyroid history), and a discussion of contraindications. Absolute contraindications include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). [1]

Most telehealth platforms connected to New York pharmacies or pharmacies that ship to New York can process both the Novo Nordisk savings card and prior authorization paperwork on the patient's behalf, reducing administrative burden significantly compared with navigating the process alone.

New York-Specific Discount Programs and Patient Assistance

Beyond the Novo Nordisk savings card, several additional programs may reduce Wegovy costs for New York residents.

NovoCare Patient Assistance Program (PAP)

Novo Nordisk's PAP provides Wegovy at no cost to uninsured or underinsured patients who meet income eligibility criteria. As of 2026, household income must generally be at or below 400% of the federal poverty level, though income thresholds are updated annually. Applications are submitted through NovoCare (1-833-NOVO-411).

New York State of Health Marketplace Plans

New Yorkers who purchase insurance through NY State of Health (the state's ACA marketplace) should check whether Silver or Gold-tier plans on their current exchange include Wegovy coverage. Plans change formularies annually at open enrollment. Selecting a plan that covers GLP-1 obesity agents during the November-to-January open enrollment window can reduce annual Wegovy spending by thousands of dollars.

Hospital-Based Obesity Programs

Several New York academic medical centers, including NYU Langone Health, Weill Cornell Medicine, and Mount Sinai's Program for Surgical Weight Loss, operate multidisciplinary obesity programs. These programs employ financial counselors who specialize in obtaining insurance coverage for anti-obesity medications. Patients enrolled in these programs may have higher prior authorization approval rates than those seeking Wegovy through a standalone primary care encounter.

Key Differences: Wegovy vs. Ozempic in New York Cost Context

Ozempic (semaglutide 0.5 mg to 2 mg) is the same molecule as Wegovy but is FDA-approved only for type 2 diabetes management. Its list price is also approximately $935 per month. Some clinicians in New York prescribe Ozempic off-label for weight loss, which may be covered by insurance when a type 2 diabetes diagnosis is present, but off-label prescribing for obesity alone creates coverage conflicts and is not the same as using the approved Wegovy formulation.

Wegovy pens are calibrated to deliver doses up to 2.4 mg per week; Ozempic tops out at 2 mg. Patients seeking the full FDA-approved weight management dose of 2.4 mg need Wegovy, not Ozempic. Substituting one for the other without prescriber guidance is clinically inappropriate.